228 related articles for article (PubMed ID: 29766327)
21. The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5.
Han B; Yao W; Oh YT; Tong JS; Li S; Deng J; Yue P; Khuri FR; Sun SY
Oncotarget; 2015 Jul; 6(19):17532-42. PubMed ID: 26009898
[TBL] [Abstract][Full Text] [Related]
22. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.
Verbrugge SE; Assaraf YG; Dijkmans BA; Scheffer GL; Al M; den Uyl D; Oerlemans R; Chan ET; Kirk CJ; Peters GJ; van der Heijden JW; de Gruijl TD; Scheper RJ; Jansen G
J Pharmacol Exp Ther; 2012 Apr; 341(1):174-82. PubMed ID: 22235146
[TBL] [Abstract][Full Text] [Related]
23. Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer.
Yin YP; Shi WH; Deng K; Liu XL; Li H; Lv XT; Lui VWY; Ding C; Hong B; Lin WC
Acta Pharmacol Sin; 2021 Aug; 42(8):1298-1310. PubMed ID: 33139838
[TBL] [Abstract][Full Text] [Related]
24. H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth.
Lee MJ; Miller Z; Park JE; Bhattarai D; Lee W; Kim KB
Sci Rep; 2019 Mar; 9(1):4089. PubMed ID: 30858500
[TBL] [Abstract][Full Text] [Related]
25. The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.
Besse L; Kraus M; Besse A; Driessen C; Tarantino I
Sci Rep; 2023 Mar; 13(1):4411. PubMed ID: 36932175
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-22 (IL-22) Regulates Apoptosis of Paclitaxel-Resistant Non-Small Cell Lung Cancer Cells Through C-Jun N-Terminal Kinase Signaling Pathway.
Li C; Zhao X; Yang Y; Liu S; Liu Y; Li X
Med Sci Monit; 2018 May; 24():2750-2757. PubMed ID: 29723165
[TBL] [Abstract][Full Text] [Related]
27. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer.
Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ
Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469
[TBL] [Abstract][Full Text] [Related]
28. Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers.
Chen YL; Yang TY; Chen KC; Wu CL; Hsu SL; Hsueh CM
Cell Oncol (Dordr); 2016 Oct; 39(5):411-433. PubMed ID: 27306525
[TBL] [Abstract][Full Text] [Related]
29. MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs.
Giaccone G; van Ark-Otte J; Rubio GJ; Gazdar AF; Broxterman HJ; Dingemans AM; Flens MJ; Scheper RJ; Pinedo HM
Int J Cancer; 1996 Jun; 66(6):760-7. PubMed ID: 8647646
[TBL] [Abstract][Full Text] [Related]
30. Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy.
Kawai H; Kiura K; Tabata M; Yoshino T; Takata I; Hiraki A; Chikamori K; Ueoka H; Tanimoto M; Harada M
Lung Cancer; 2002 Mar; 35(3):305-14. PubMed ID: 11844606
[TBL] [Abstract][Full Text] [Related]
31. Carfilzomib inhibits the growth of lung adenocarcinoma via upregulation of Gadd45a expression.
Yang F; Liu WW; Chen H; Zhu J; Huang AH; Zhou F; Gan Y; Zhang YH; Ma L
J Zhejiang Univ Sci B; 2020 Jan.; 21(1):64-76. PubMed ID: 31898443
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory effect of Ubenimex combined with fluorouracil on multiple drug resistance and P-glycoprotein expression level in non-small lung cancer.
Wan J; Ling XA; Wang J; Ding GG; Wang X
J Cell Mol Med; 2020 Nov; 24(21):12840-12847. PubMed ID: 32945069
[TBL] [Abstract][Full Text] [Related]
33. Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoprotein.
Lehne G; Rugstad HE
Br J Cancer; 1998 Sep; 78(5):593-600. PubMed ID: 9744497
[TBL] [Abstract][Full Text] [Related]
34. Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells.
Li Y; Hu T; Chen T; Yang T; Ren H; Chen M
Oncol Rep; 2018 Feb; 39(2):565-572. PubMed ID: 29207165
[TBL] [Abstract][Full Text] [Related]
35. Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells.
Shi Y; Yu Y; Wang Z; Wang H; Bieerkehazhi S; Zhao Y; Suzuk L; Zhang H
Oncotarget; 2016 Nov; 7(45):73697-73710. PubMed ID: 27655642
[TBL] [Abstract][Full Text] [Related]
36. Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure.
Guo B; Villeneuve DJ; Hembruff SL; Kirwan AF; Blais DE; Bonin M; Parissenti AM
Breast Cancer Res Treat; 2004 May; 85(1):31-51. PubMed ID: 15039596
[TBL] [Abstract][Full Text] [Related]
37. Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1.
Hawley TS; Riz I; Yang W; Wakabayashi Y; Depalma L; Chang YT; Peng W; Zhu J; Hawley RG
Am J Hematol; 2013 Apr; 88(4):265-72. PubMed ID: 23475625
[TBL] [Abstract][Full Text] [Related]
38. Role of RLIP76 in lung cancer doxorubicin resistance: I. The ATPase activity of RLIP76 correlates with doxorubicin and 4-hydroxynonenal resistance in lung cancer cells.
Singhal SS; Singhal J; Sharma R; Singh SV; Zimniak P; Awasthi YC; Awasthi S
Int J Oncol; 2003 Feb; 22(2):365-75. PubMed ID: 12527936
[TBL] [Abstract][Full Text] [Related]
39. GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin.
Gong X; Liu J; Zhang D; Yang D; Min Z; Wen X; Wang G; Li H; Song Y; Bai C; Li J; Zhou J
PLoS One; 2017; 12(8):e0182410. PubMed ID: 28771580
[TBL] [Abstract][Full Text] [Related]
40. Acacetin enhances the therapeutic efficacy of doxorubicin in non-small-cell lung carcinoma cells.
Punia R; Raina K; Agarwal R; Singh RP
PLoS One; 2017; 12(8):e0182870. PubMed ID: 28859099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
